CureVac NV (CVAC)
3.33
-0.15
(-4.31%)
USD |
NASDAQ |
Jun 18, 10:12
CureVac Cash from Financing (Quarterly): -1.221M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.221M |
| December 31, 2023 | -2.960M |
| September 30, 2023 | -1.704M |
| June 30, 2023 | 2.545M |
| March 31, 2023 | 252.09M |
| December 31, 2022 | 36.53M |
| September 30, 2022 | 26.46M |
| June 30, 2022 | 4.147M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.5162M |
| December 31, 2021 | -38.09M |
| September 30, 2021 | -10.33M |
| June 30, 2021 | -29.77M |
| March 31, 2021 | 486.35M |
| March 31, 2020 | 20.68M |
| March 31, 2019 | -0.3169M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-38.09M
Minimum
Dec 2021
486.35M
Maximum
Mar 2021
53.16M
Average
1.014M
Median
Cash from Financing (Quarterly) Benchmarks
| BioNTech SE | -8.472M |
| Affimed NV | -0.4529M |
| Moderna Inc | 14.00M |
| InflaRx NV | -0.0931M |
| MorphoSys AG | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -104.88M |
| Cash from Investing (Quarterly) | -5.527M |
| Free Cash Flow | -339.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4922 |
| Free Cash Flow to Equity (Quarterly) | -110.40M |
| Free Cash Flow to Firm (Quarterly) | -110.40M |
| Free Cash Flow Yield | -45.45% |